Cargando…

NUCB2/Nesfatin-1 drives breast cancer metastasis through the up-regulation of cholesterol synthesis via the mTORC1 pathway

BACKGROUND: Reprogramming lipid metabolism for tumor metastasis is essential in breast cancer, and NUCB2/Nesfatin-1 plays a crucial role in regulating energy metabolism. Its high expression is associated with poor prognosis in breast cancer. Here, we studied whether NUCB2/Nesfatin-1 promotes breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Ning, Siyi, Liu, Caiying, Wang, Kangtao, Cai, Yubo, Ning, Zhicheng, Li, Ming, Zeng, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243030/
https://www.ncbi.nlm.nih.gov/pubmed/37277807
http://dx.doi.org/10.1186/s12967-023-04236-x
_version_ 1785054343697793024
author Ning, Siyi
Liu, Caiying
Wang, Kangtao
Cai, Yubo
Ning, Zhicheng
Li, Ming
Zeng, Liang
author_facet Ning, Siyi
Liu, Caiying
Wang, Kangtao
Cai, Yubo
Ning, Zhicheng
Li, Ming
Zeng, Liang
author_sort Ning, Siyi
collection PubMed
description BACKGROUND: Reprogramming lipid metabolism for tumor metastasis is essential in breast cancer, and NUCB2/Nesfatin-1 plays a crucial role in regulating energy metabolism. Its high expression is associated with poor prognosis in breast cancer. Here, we studied whether NUCB2/Nesfatin-1 promotes breast cancer metastasis through reprogramming cholesterol metabolism. METHODS: ELISA was employed to measure the concentration of Nesfatin-1 in the serum of breast cancer patients and the control group. Database analysis suggested that NUCB2/Nesfatin-1 might be acetylated in breast cancer, which was confirmed by treating the breast cancer cells with acetyltransferase inhibitors. Transwell migration and Matrigel invasion assays were conducted, and nude mouse lung metastasis models were established to examine the effect of NUCB2/Nesfatin-1 on breast cancer metastasis in vitro and in vivo. The Affymetrix gene expression chip results were analyzed using IPA software to identify the critical pathway induced by NUCB2/Nesfatin-1. We evaluated the effect of NUCB2/Nesfatin-1 on cholesterol biosynthesis through the mTORC1-SREBP2-HMGCR axis by utilizing mTORC1 inhibitor and rescue experiments. RESULTS: NUCB2/Nesfatin-1 was found to be overexpressed in the breast cancer patients, and its overexpression was positively correlated with poor prognosis. NUCB2 was potentially acetylated, leading to high expression in breast cancer. NUCB2/Nesfatin-1 promoted metastasis in vitro and in vivo, while Nesfatin-1 rescued impaired cell metastasis induced by NUCB2 depletion. Mechanistically, NUCB2/Nesfatin-1 upregulated cholesterol synthesis via the mTORC1 signal pathway, contributing to breast cancer migration and metastasis. CONCLUSIONS: Our findings demonstrate that the NUCB2/Nesfatin-1/mTORC1/SREBP2 signal pathway is critical in regulating cholesterol synthesis, essential for breast cancer metastasis. Thus, NUCB2/Nesfatin-1 might be utilized as a diagnostic tool and also used in cancer therapy for breast cancer in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04236-x.
format Online
Article
Text
id pubmed-10243030
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102430302023-06-07 NUCB2/Nesfatin-1 drives breast cancer metastasis through the up-regulation of cholesterol synthesis via the mTORC1 pathway Ning, Siyi Liu, Caiying Wang, Kangtao Cai, Yubo Ning, Zhicheng Li, Ming Zeng, Liang J Transl Med Research BACKGROUND: Reprogramming lipid metabolism for tumor metastasis is essential in breast cancer, and NUCB2/Nesfatin-1 plays a crucial role in regulating energy metabolism. Its high expression is associated with poor prognosis in breast cancer. Here, we studied whether NUCB2/Nesfatin-1 promotes breast cancer metastasis through reprogramming cholesterol metabolism. METHODS: ELISA was employed to measure the concentration of Nesfatin-1 in the serum of breast cancer patients and the control group. Database analysis suggested that NUCB2/Nesfatin-1 might be acetylated in breast cancer, which was confirmed by treating the breast cancer cells with acetyltransferase inhibitors. Transwell migration and Matrigel invasion assays were conducted, and nude mouse lung metastasis models were established to examine the effect of NUCB2/Nesfatin-1 on breast cancer metastasis in vitro and in vivo. The Affymetrix gene expression chip results were analyzed using IPA software to identify the critical pathway induced by NUCB2/Nesfatin-1. We evaluated the effect of NUCB2/Nesfatin-1 on cholesterol biosynthesis through the mTORC1-SREBP2-HMGCR axis by utilizing mTORC1 inhibitor and rescue experiments. RESULTS: NUCB2/Nesfatin-1 was found to be overexpressed in the breast cancer patients, and its overexpression was positively correlated with poor prognosis. NUCB2 was potentially acetylated, leading to high expression in breast cancer. NUCB2/Nesfatin-1 promoted metastasis in vitro and in vivo, while Nesfatin-1 rescued impaired cell metastasis induced by NUCB2 depletion. Mechanistically, NUCB2/Nesfatin-1 upregulated cholesterol synthesis via the mTORC1 signal pathway, contributing to breast cancer migration and metastasis. CONCLUSIONS: Our findings demonstrate that the NUCB2/Nesfatin-1/mTORC1/SREBP2 signal pathway is critical in regulating cholesterol synthesis, essential for breast cancer metastasis. Thus, NUCB2/Nesfatin-1 might be utilized as a diagnostic tool and also used in cancer therapy for breast cancer in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04236-x. BioMed Central 2023-06-05 /pmc/articles/PMC10243030/ /pubmed/37277807 http://dx.doi.org/10.1186/s12967-023-04236-x Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ning, Siyi
Liu, Caiying
Wang, Kangtao
Cai, Yubo
Ning, Zhicheng
Li, Ming
Zeng, Liang
NUCB2/Nesfatin-1 drives breast cancer metastasis through the up-regulation of cholesterol synthesis via the mTORC1 pathway
title NUCB2/Nesfatin-1 drives breast cancer metastasis through the up-regulation of cholesterol synthesis via the mTORC1 pathway
title_full NUCB2/Nesfatin-1 drives breast cancer metastasis through the up-regulation of cholesterol synthesis via the mTORC1 pathway
title_fullStr NUCB2/Nesfatin-1 drives breast cancer metastasis through the up-regulation of cholesterol synthesis via the mTORC1 pathway
title_full_unstemmed NUCB2/Nesfatin-1 drives breast cancer metastasis through the up-regulation of cholesterol synthesis via the mTORC1 pathway
title_short NUCB2/Nesfatin-1 drives breast cancer metastasis through the up-regulation of cholesterol synthesis via the mTORC1 pathway
title_sort nucb2/nesfatin-1 drives breast cancer metastasis through the up-regulation of cholesterol synthesis via the mtorc1 pathway
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243030/
https://www.ncbi.nlm.nih.gov/pubmed/37277807
http://dx.doi.org/10.1186/s12967-023-04236-x
work_keys_str_mv AT ningsiyi nucb2nesfatin1drivesbreastcancermetastasisthroughtheupregulationofcholesterolsynthesisviathemtorc1pathway
AT liucaiying nucb2nesfatin1drivesbreastcancermetastasisthroughtheupregulationofcholesterolsynthesisviathemtorc1pathway
AT wangkangtao nucb2nesfatin1drivesbreastcancermetastasisthroughtheupregulationofcholesterolsynthesisviathemtorc1pathway
AT caiyubo nucb2nesfatin1drivesbreastcancermetastasisthroughtheupregulationofcholesterolsynthesisviathemtorc1pathway
AT ningzhicheng nucb2nesfatin1drivesbreastcancermetastasisthroughtheupregulationofcholesterolsynthesisviathemtorc1pathway
AT liming nucb2nesfatin1drivesbreastcancermetastasisthroughtheupregulationofcholesterolsynthesisviathemtorc1pathway
AT zengliang nucb2nesfatin1drivesbreastcancermetastasisthroughtheupregulationofcholesterolsynthesisviathemtorc1pathway